Actively Recruiting
RhEumatoid Arthritis MEDIcation Adherence
Led by Hospices Civils de Lyon · Updated on 2025-10-02
200
Participants Needed
2
Research Sites
287 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.
CONDITIONS
Official Title
RhEumatoid Arthritis MEDIcation Adherence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with rheumatoid arthritis (RA)
- Male or female aged 18 years or older
- Hospitalized or had a consultation in a rheumatology department and returned home after discharge
- Receiving disease-modifying antirheumatic drugs (DMARDs) for RA, including methotrexate, targeted synthetic DMARDs (JAK inhibitors), or subcutaneous biologic DMARDs
- Able to manage own medication treatment independently
- Understands and speaks French
- Affiliated with French national health insurance or similar
- Provided free, informed, and signed consent to participate
You will not qualify if you...
- Usual pharmacy already has or had a patient in the study's intervention group
- Regular pharmacy currently treating another patient
- Significant cognitive or psychiatric disorders incompatible with the study
- Medication management at home done exclusively by a caregiver
- Participating in another research that may interfere with study results
- Adult under legal protection (Public Health Code)
- Not fit to complete study follow-up
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon
Pierre-Bénite, Lyon, France, 69495
Not Yet Recruiting
2
Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot
Lyon, France, 69003
Actively Recruiting
Research Team
R
Roland CHAPURLAT, MD/PHD
CONTACT
A
Audrey JANOLY-DUMENIL, PharmD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here